drugset
drugset / Trial / NCT05057897

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

NCT05057897 ↗

Phase 4 Terminated 34 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.

Timeline

Start
2022-01-31
Primary completion
2023-04-19
Completion
2023-04-19

Outcome

Outcome not reported

Stopped (Enrollment): “Removal of the commitment for Immune compromised study (D81111C00010) due to recruitment challenges.”

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1222 Vaccine — Intramuscular

Indications

COVID-19